ArticleThe journal of prevention of Alzheimer's disease2024
Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform.
Article in The journal of prevention of Alzheimer's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07731191 (Development of Digital Solutions for the Prediction of the Biological Mechanisms of Alzheimer's Disease Through the Analysis of Risk Factors), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Development of Digital Solutions for the Prediction of the Biological Mechanisms of Alzheimer's Disease Through the Analysis of Risk Factors (PrevAI)
Who cites it
10 citing papers in PubMed.
- Association of tongue, handgrip, and pinch strength with blood-based phosphorylated-tau 181 in cognitively healthy older adults.GeroScience · 2026Article
- CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression.medRxiv : the preprint server for health sciences · 2026Article
- Plasma p-tau217, quantified by the fully automated LUMIPULSE G platform, outperforms p-tau181 in predicting amyloid pathology in cognitive complaints patients.Scientific reports · 2026Article
- Plasma phospho-tau 217 outperforms plasma phospho-tau 181 analyzed with Lumipulse in detecting Alzheimer's dementia in a real-world memory clinic population.Frontiers in aging neuroscience · 2026Article
- Clinical validation of new alzheimer disease diagnosis tools based on plasma p-Tau217.Scientific reports · 2025Article
- Plasma phosphorylated tau 217 and amyloid‑β 42/40 for amyloid risk in subgroups.Alzheimer's research & therapy · 2025Article
- Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use.The journal of prevention of Alzheimer's disease · 2025Review
- Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform.Alzheimer's research & therapy · 2025Article
- Longitudinal trajectory of plasma p-tau217 in cognitively unimpaired subjects.Alzheimer's research & therapy · 2024Article
- The two cut-offs approach for plasma p-tau217 in detecting Alzheimer's disease in subjective cognitive decline and mild cognitive impairment.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlasma biomarkers of Alzheimer's disease (AD), especially p-tau217, are promising tools to identify subjects with amyloid deposition in the brain, determined either by cerebrospinal fluid (CSF) or positron emission tomography. However, it is essential to measure them in an accurate and fully automated way in order to apply them in clinical practice.
objectivesTo evaluate the diagnostic performance of the fully-automated Lumipulse plasma p-tau217 assay in preclinical AD.
designCross-sectional analyses from a prospective cohort.
settingA population-based study.
participantsVolunteers over 55 years without cognitive impairment or contraindications for complementary tests. MEASUREMENTS: Plasma p-tau217 was measured with the fully-automated Lumipulse assay, as well as CSF Aβ40, Aβ42, p-tau181, and t-tau levels. We correlated plasma p-tau217 with CSF Aβ40, Aβ42 and p-tau181, and assessed the differences in plasma p-tau217 according to CSF amyloid status (A-/+), AD status (AD+ being those subjects A+T+ and AD- the rest) and ATN group. We performed ROC curves and measured the areas under the curve (AUC) using CSF amyloid as result, and both p-tau217 and ApoE4 status as predictor.
resultsWe screened 209 cognitively unimpaired volunteers with a mean age 64 years (60-69) and 30.2% of ApoE4 carriers. Plasma p-tau217 correlated significantly with CSF Aβ42/Aβ40 (Rho=-0.51; p-value<0.001) and p-tau181 (r=0.59; p-value<0.001). Its levels were significantly higher in A+ subjects (0.26 pg/ml) compared with A- (0.12 pg/ml; p-value<0.001); and along ATN groups. It predicts CSF amyloid pathology with an AUC of 0.85.
conclusionsPlasma p-tau217 measured using the Lumipulse platform shows promise as an accurate biomarker of preclinical AD pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.